vs
Carter Bankshares, Inc.（CARE）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Carter Bankshares, Inc.的季度营收约是REGENXBIO Inc.的1.3倍（$39.8M vs $30.3M），REGENXBIO Inc.同比增速更快（43.0% vs 15.4%），Carter Bankshares, Inc.自由现金流更多（$31.8M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 9.1%）
卡特银行股份有限公司是美国区域性银行控股企业，旗下运营卡特银行与信托机构，提供零售及商业银行服务，包含存款账户、个人及商业贷款、财富管理等产品，主要服务弗吉尼亚州和北卡罗来纳州的本地居民及中小商业客户。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CARE vs RGNX — 直观对比
营收规模更大
CARE
是对方的1.3倍
$30.3M
营收增速更快
RGNX
高出27.6%
15.4%
自由现金流更多
CARE
多$84.6M
$-52.8M
两年增速更快
RGNX
近两年复合增速
9.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $39.8M | $30.3M |
| 净利润 | — | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 27.8% | -190.0% |
| 净利率 | — | -221.3% |
| 营收同比 | 15.4% | 43.0% |
| 净利润同比 | — | -31.2% |
| 每股收益（稀释后） | $0.38 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CARERGNX
| Q4 25 | $39.8M | $30.3M | ||
| Q3 25 | $39.1M | $29.7M | ||
| Q2 25 | $37.3M | $21.4M | ||
| Q1 25 | $37.0M | $89.0M | ||
| Q4 24 | $34.5M | $21.2M | ||
| Q3 24 | $34.2M | $24.2M | ||
| Q2 24 | $33.6M | $22.3M | ||
| Q1 24 | $33.5M | $15.6M |
净利润CARERGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $5.4M | $-61.9M | ||
| Q2 25 | $8.5M | $-70.9M | ||
| Q1 25 | $9.0M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $5.6M | $-59.6M | ||
| Q2 24 | $4.8M | $-53.0M | ||
| Q1 24 | $5.8M | $-63.3M |
毛利率CARERGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率CARERGNX
| Q4 25 | 27.8% | -190.0% | ||
| Q3 25 | 18.3% | -176.3% | ||
| Q2 25 | 28.5% | -296.3% | ||
| Q1 25 | 30.1% | 13.6% | ||
| Q4 24 | 31.0% | -242.1% | ||
| Q3 24 | 20.5% | -256.6% | ||
| Q2 24 | 17.6% | -251.3% | ||
| Q1 24 | 21.6% | -408.8% |
净利率CARERGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | 13.9% | -208.3% | ||
| Q2 25 | 22.8% | -331.8% | ||
| Q1 25 | 24.2% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 16.4% | -246.3% | ||
| Q2 24 | 14.3% | -237.7% | ||
| Q1 24 | 17.4% | -405.4% |
每股收益（稀释后）CARERGNX
| Q4 25 | $0.38 | $-1.30 | ||
| Q3 25 | $0.24 | $-1.20 | ||
| Q2 25 | $0.37 | $-1.38 | ||
| Q1 25 | $0.39 | $0.12 | ||
| Q4 24 | $0.36 | $-0.99 | ||
| Q3 24 | $0.24 | $-1.17 | ||
| Q2 24 | $0.21 | $-1.05 | ||
| Q1 24 | $0.25 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $419.7M | $102.7M |
| 总资产 | $4.9B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CARERGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益CARERGNX
| Q4 25 | $419.7M | $102.7M | ||
| Q3 25 | $412.8M | $161.5M | ||
| Q2 25 | $405.6M | $213.7M | ||
| Q1 25 | $401.8M | $274.2M | ||
| Q4 24 | $384.3M | $259.7M | ||
| Q3 24 | $386.8M | $301.4M | ||
| Q2 24 | $364.4M | $348.3M | ||
| Q1 24 | $359.1M | $390.7M |
总资产CARERGNX
| Q4 25 | $4.9B | $453.0M | ||
| Q3 25 | $4.8B | $525.2M | ||
| Q2 25 | $4.8B | $581.0M | ||
| Q1 25 | $4.7B | $490.9M | ||
| Q4 24 | $4.7B | $466.0M | ||
| Q3 24 | $4.6B | $519.1M | ||
| Q2 24 | $4.5B | $569.4M | ||
| Q1 24 | $4.6B | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $39.9M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $31.8M | $-52.8M |
| 自由现金流率自由现金流/营收 | 79.9% | -174.0% |
| 资本支出强度资本支出/营收 | 20.2% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $54.6M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CARERGNX
| Q4 25 | $39.9M | $-52.3M | ||
| Q3 25 | $11.8M | $-56.0M | ||
| Q2 25 | $9.6M | $-49.3M | ||
| Q1 25 | $6.4M | $33.6M | ||
| Q4 24 | $36.9M | $-31.6M | ||
| Q3 24 | $10.3M | $-40.5M | ||
| Q2 24 | $-2.5M | $-45.5M | ||
| Q1 24 | $17.6M | $-55.5M |
自由现金流CARERGNX
| Q4 25 | $31.8M | $-52.8M | ||
| Q3 25 | $10.3M | $-56.5M | ||
| Q2 25 | $7.7M | $-49.7M | ||
| Q1 25 | $4.9M | $32.6M | ||
| Q4 24 | $28.8M | $-32.7M | ||
| Q3 24 | $8.4M | $-40.9M | ||
| Q2 24 | $-4.3M | $-46.0M | ||
| Q1 24 | $16.3M | $-56.0M |
自由现金流率CARERGNX
| Q4 25 | 79.9% | -174.0% | ||
| Q3 25 | 26.3% | -189.9% | ||
| Q2 25 | 20.6% | -232.8% | ||
| Q1 25 | 13.1% | 36.6% | ||
| Q4 24 | 83.5% | -154.2% | ||
| Q3 24 | 24.6% | -168.9% | ||
| Q2 24 | -12.7% | -206.2% | ||
| Q1 24 | 48.8% | -358.5% |
资本支出强度CARERGNX
| Q4 25 | 20.2% | 1.7% | ||
| Q3 25 | 3.9% | 1.7% | ||
| Q2 25 | 5.1% | 1.8% | ||
| Q1 25 | 4.1% | 1.2% | ||
| Q4 24 | 23.6% | 5.1% | ||
| Q3 24 | 5.5% | 1.3% | ||
| Q2 24 | 5.4% | 2.1% | ||
| Q1 24 | 3.9% | 3.6% |
现金转化率CARERGNX
| Q4 25 | — | — | ||
| Q3 25 | 2.18× | — | ||
| Q2 25 | 1.13× | — | ||
| Q1 25 | 0.71× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.83× | — | ||
| Q2 24 | -0.51× | — | ||
| Q1 24 | 3.03× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CARE
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
